Latest Developments in Global Palmoplantar Pustulosis Market

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Global Palmoplantar Pustulosis Market

  • Pharmaceutical
  • Upcoming Report
  • Dec 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In March 2024, Amgen announced new 52-week results from the Phase 3 SPROUT study on Otezla (apremilast) in children and adolescents (6-17 years) with moderate to severe plaque psoriasis. Additionally, Phase 3 late-breaking study results on Otezla in palmoplantar pustulosis will be presented at the 2024 AAD Annual Meeting in San Diego. These findings will enhance Amgen's market position by showcasing Otezla’s efficacy in diverse dermatological conditions, expanding its potential patient base
  • In August 2023, Kyowa Kirin Co., Ltd. announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for a partial change in the approved indication of LUMICEF (brodalumab) to treat palmoplantar pustulosis (PPP) in patients who do not respond adequately to existing therapies. This approval will enhance the company's portfolio, offering a new treatment option for PPP patients and expanding its presence in the dermatology market.

Frequently Asked Questions

The market is segmented based on Segmentation, By Type of Treatment (Topical Treatments, Systemic Treatments, Phototherapy, and Surgical Treatments), Drug Class (Biologics, Immunosuppressants, Topical Steroids, and Others), Disease Severity (Mild, Moderate, and Severe), End User (Hospitals and Clinics, Home Care, and Research Institutions) – Industry Trends and Forecast to 2032 .
The Global Palmoplantar Pustulosis Market size was valued at USD 522.36 USD Billion in 2024.
The Global Palmoplantar Pustulosis Market is projected to grow at a CAGR of 9.2% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.